Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer.

Autor: Maggadottir SM; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway; Landspitali University Hospital, Reykjavik, Iceland., Dueland S; Department of Oncology, Oslo University Hospital, Oslo, Norway., Mensali N; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Hamre H; Department of Oncology, Akershus University Hospital, Lørenskog, Norway., Andresen PA; Department of Pathology, Oslo University Hospital, Oslo, Norway., Myhre MR; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Juul HV; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Bigalke I; Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Lundby M; Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Hønnåshagen TK; Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Sæbøe-Larssen S; Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Josefsen D; Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Hagtvedt T; Department of Radiology, Oslo University Hospital, Oslo, Norway., Wälchli S; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Kvalheim G; Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Inderberg EM; Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway. Electronic address: elsin@rr-research.no.

Publikováno v: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2024 Jun 05; Vol. 32 (6), pp. 2021-2029. Date of Electronic Publication: 2024 Apr 06.

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.

Autor: Mensali N; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Köksal H; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Joaquina S; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Wernhoff P; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Casey NP; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Romecin P; Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain., Panisello C; Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain., Rodriguez R; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Hospital Universitario Central de Asturias, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBER-ONC), Instituto de Salud Carlos III, Madrid, Spain., Vimeux L; Université de Paris, Institut Cochin, INSERM, CNRS, Equipe labellisée Ligue Contre le Cancer, F-75014, PARIS, France., Juzeniene A; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Myhre MR; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Fåne A; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Ramírez CC; Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital, CSIC, University of Sevilla, CIBER-ONC, 41013, Seville, Spain., Maggadottir SM; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Duru AD; NSU Cell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA., Georgoudaki AM; NSU Cell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA.; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Grad I; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Maturana AD; Laboratory of Animal Cell Physiology, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya, Japan., Gaudernack G; Department of Cancer Immunology, Oslo University Hospital, Oslo, Norway., Kvalheim G; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Carcaboso AM; SJD Pediatric Cancer Center Barcelona, Institut de Recerca Sant Joan de Deu, Barcelona, 08950, Spain., de Alava E; Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital, CSIC, University of Sevilla, CIBER-ONC, 41013, Seville, Spain.; Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, 41009, Seville, Spain., Donnadieu E; Université de Paris, Institut Cochin, INSERM, CNRS, Equipe labellisée Ligue Contre le Cancer, F-75014, PARIS, France., Bruland ØS; Department of Oncology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Menendez P; Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain.; CIBER-ONC, ISCIII, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.; Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain., Inderberg EM; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway. elsin@rr-research.no., Wälchli S; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway. sebastw@rr-research.no.

Publikováno v: Nature communications [Nat Commun] 2023 Jun 08; Vol. 14 (1), pp. 3375. Date of Electronic Publication: 2023 Jun 08.

Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.

Autor: Dillard P; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway., Köksal H; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway., Maggadottir SM; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway., Winge-Main A; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway., Pollmann S; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway., Menard M; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway., Myhre MR; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway., Mælandsmo GM; Department of Tumor Biology, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway., Flørenes VA; Department of Pathology, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway., Gaudernack G; Department of Cancer Immunology, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway., Kvalheim G; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway., Wälchli S; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway. Electronic address: sebastw@rr-research.no., Inderberg EM; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, 0379 Oslo, Norway. Electronic address: elsin@rr-research.no.

Publikováno v: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2021 Mar 03; Vol. 29 (3), pp. 1199-1213. Date of Electronic Publication: 2020 Nov 17.

Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.

Autor: Mensali N; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway., Myhre MR; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway., Dillard P; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway., Pollmann S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway., Gaudernack G; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway.; Faculty of Medicine, University of Oslo, 0316, Oslo, Norway., Kvalheim G; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway., Wälchli S; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway. sebastw@rr-research.no., Inderberg EM; Department of Cellular Therapy, Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, 0379, Oslo, Norway. elsmar@rr-research.no.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2019 Aug; Vol. 68 (8), pp. 1235-1243. Date of Electronic Publication: 2019 Jun 18.